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For decades the default treatment for anaemia and bleeding was 
mostly blood transfusion. However, safety risks from new and 
re-emerging pathogens in the blood pool,[1-3] significant inter- and 
intrahospital transfusion variability for matched patients,[4-9] the high 
cost of transfusion therapy,[10,11] and in particular the large number of 
risk-adjusted observational studies demonstrating that transfusion 
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For more than 70 years the default therapy for anaemia and blood loss was mostly transfusion. Accumulating evidence demonstrates a 
significant dose-dependent relationship between transfusion and adverse outcomes. This and other transfusion-related challenges led the 
way to a new paradigm. Patient blood management (PBM) is the application of evidence-based practices to optimise patient outcomes by 
managing and preserving the patient’s own blood. ‘Real-world’ studies have shown that PBM improves patient outcomes and saves money. 
The prevalence of anaemia in adult South Africans is 31% in females and 17% in males. Improving the management of anaemia will firstly 
improve public health, secondly relieve the pressure on the blood supply, and thirdly improve the productivity of the nation’s workforce. 
While high-income countries are increasingly implementing PBM, many middle- and low-income countries are still trying to upscale their 
transfusion services. The implementation of PBM will improve South Africa’s health status while saving costs.
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is independently associated in a dose-dependent relationship with 
adverse outcomes including morbidity and mortality,[12-25] have led 
to questioning of the transfusion paradigm.[26,27] Also, systematic 
reviews and meta-analyses of randomised controlled trials have 
shown either no benefit or increased risks from liberal transfusion 
regimens when compared with more restrictive regimens.[28-32] In 
response to these challenges and with the objectives of better 
addressing the causes or underlying diseases that could potentially 
lead to allogeneic transfusions and offering the best choice of therapy, 
the new paradigm of patient blood management (PBM) has emerged.
PBM is described by the International Foundation for Patient 
Blood Management as ‘an evidence-based bundle of care to optimize 
medical and surgical patient outcomes by clinically managing and 
preserving a patient’s blood’.[33] This is achieved by optimising 
erythropoiesis, minimising blood loss and harnessing or optimising 
the physiological reserves of anaemia while appropriate therapy 
is instituted, often referred to as the ‘three pillars of patient blood 
management’ (Fig. 1). This concept was adopted by the World 
Health Assembly resolution WHA63.12 in 2010.[34] A similar and 
widely used description of PBM by the Society for the Advancement 
of Blood Management is ‘the timely application of evidence-based 
medical and surgical concepts designed to maintain hemoglobin 
concentration, optimize hemostasis and minimize blood loss in an 
effort to improve patient outcome’.[35]
A number of large observational PBM studies have demonstrated 
significantly improved patient outcomes including mortality, 
morbidity and average length of hospital stay,[36-39] one of these 
being a recent ‘real-world study’ with 605 046 patients within the 
jurisdiction of Western Australia (Table 1).[40] Also, a growing number 
of randomised controlled trials looking at single PBM treatment 
modalities showed significantly improved patient outcomes with 
concurrent reduction of blood component utilisation.[41,42] Overall, 
PBM has demonstrated improved outcomes while reducing cost 
and/or resource utilisation (blood components) with the potential to 
repurpose those savings.
PBM as a standard of care
PBM has the potential to address several healthcare-related 
challenges that are specific to South Africa (SA).
First, the population of SA totalled 57.8 million in 2018[43] 
and included an estimated 17.8 million people suffering from 
anaemia, mostly neonates and children, women of reproductive 
age, and the elderly.[44-47] Apart from iron deficiency anaemia, 
there is also a high prevalence of HIV-related anaemia, anaemia 
of inflammation, malarial anaemia and anaemia from intestinal 
parasite infestations. In hospitalised patients, the prevalence of 
anaemia is even higher than in the general population, and 
it is an independent predictor for adverse outcomes including 
morbidity and mortality. [48,49] A secondary analysis of the South 
African Surgical Outcomes Study (SASOS), a large prospective 
observational study of patients undergoing inpatient non-cardiac, 
non-obstetric surgery at 50  hospitals across SA over a 7-day 
period, showed that the prevalence of preoperative anaemia was 
47.8% and that it was independently associated with an increase 
in in-hospital mortality (odds ratio (OR) 1.657, 95% confidence 
interval (CI) 1.055 - 2.602; p=0.028) and admission to critical care 
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• Identify underlying disorder/s causing anaemia
• Manage disorder/s
• Refer for further evaluation if necessary
• Treat suboptimal iron stores/iron deciency/
  anaemia of chronic disease/iron-restricted 
  erythropoiesis
• Treat other haematinic deciencies
• Note: Anaemia is a contraindication to elective 
  surgery
• Time surgery with haematological optimisation
• Optimise erythropoiesis
• Be aware of drug interactions that can increase 
  anaemia
• Identify and manage bleeding risk
• Minimise iatrogenic blood loss
• Procedure planning and rehearsal
• Meticulous haemostasis and surgical techniques
• Blood-sparing surgical devices
• Anaesthetic blood-conserving strategies
• Autologous blood options
• Maintain normothermia
• Pharmacological/haemostatic agents
• Vigilant monitoring and management of 
  postoperative bleeding
• Avoid secondary haemorrhage
• Rapid warming/maintain normothermia 
  (unless hypothermia specically indicated)
• Autologous blood salvage
• Minimise iatrogenic blood loss
• Haemostasis/anticoagulation management
• Prophylaxis of upper GI haemorrhage
• Avoid/treat infections promptly
• Be aware of adverse eects of medication
• Assess/optimise patient's physiological reserve and 
  risk factors
• Compare estimated blood loss with patient-specic 
  tolerable blood loss
• Formulate patient-specic management plan using 
  appropriate blood-conservation modalities to 
  minimise blood loss, optimise red cell mass and 
  manage anaemia
• Optimise cardiac output
• Optimise ventilation and oxygenation
• Optimise anaemia reserve
• Maximise oxygen delivery
• Minimise oxygen consumption
• Avoid/treat infections promptly
• Restrictive transfusion thresholds
Perioperative multidisciplinary multimodal patient-specic team approach
Second pillar
Minimise blood loss and bleeding
Third pillar
Harness and optimise 
physiological reserve of anaemia
Fig. 1. The three-pillar, nine-field matrix of PBM. This matrix was designed for the Western Australia Patient Blood Management Program to assist in 
the clinical implementation of the multiple PBM strategies. These strategies are considered in the perioperative period in a patient- and procedure-specific 
context. [89] The principles of this matrix were also applied to non-surgical patients before, during and after treatment. (PBM = patient blood management.)
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(OR 1.487, 95% CI  1.081 - 2.046; p=0.015).[50] For these reasons, 
the implementation of PBM including anaemia management and 
bleeding management represents a major opportunity to sustainably 
improve public health in SA in respect of:
• child mortality
• maternal mortality (particularly related to peri- and postpartum 
haemorrhage)
• anaemia-related adverse outcomes
• blood loss and bleeding-related adverse outcomes
• transfusion-related adverse outcomes
• overall surgical and medical outcomes in hospitalised patients.
Second, the implementation of PBM would ease the pressure on 
the nation’s blood supply. The high prevalence of anaemia, the 
high prevalence of HIV with the world’s highest absolute number 
of cases,[51] and other frequently occurring diseases have led to a 
particularly high rate of 20% blood donor deferrals (Dr Jaqueline 
Thomson, Medical Director, South African National Blood Service, 
personal communication, 2018). At the same time, the demand for 
blood components is expected to increase owing to HIV-related 
anaemia and the population segment aged ≥65 years that is now 
growing faster than previously.[52] As a consequence, the prevalence 
of chronic disease and surgical procedures is expected to rise, with a 
concomitant increased demand for blood unless there are immediate 
and widespread practice changes.
Third, there is also an overall economic argument for the 
implementation of PBM. Unmanaged or poorly managed anaemia 
impairs the cognitive development of children and adolescents, 
reduces the ability to concentrate, and diminishes work productivity 
with losses in some countries of up to 9% of the gross domestic 
product.[53] Programmes promoting oral iron therapy may be 
effective in specific subpopulations, but in patients with profound 
iron deficiency and iron deficiency anaemia, who require therapy 
for immediate correction, an appropriate dose of intravenous iron 
is the best option, while treatment of the underlying cause produces 
a cure. [54] Improvements in patient outcomes with the concomitant 
savings as seen in previous studies could lead to a significant decrease 
in bed occupation and relieve a healthcare budget under extreme 
pressure.[42,55]
Contradictory developments:  
PBM for high-income countries  
and transfusion for the rest?
In the healthcare systems of the advanced economies, both the 
private and public sectors have begun to move their focus towards 
pre-empting the causes for transfusion through PBM rather than 
expanding the infrastructure to advance transfusion therapy.[56] 
The full implementation of PBM as a bundle of care is challenging, 
and some institutions are therefore following the recommendation 
of a stepwise implementation by introducing a series of simple 
PBM measures.[57,58] Others are choosing comprehensive change 
management methodologies and multi-stakeholder management 
to achieve relatively fast and system-wide implementation.[40] The 
variable implementation methodologies, and also differences in 
hospital cultures, may explain why the implementation of PBM 
remains extremely variable across many of the high-income 
countries. [59] However, the underlying rationale for this patient-centric 
approach is simple and compelling: PBM is not only associated with 
a better outcome, but also with less cost.[36,38,40] Consequently, PBM 
keeps growing while blood services are experiencing a significant 
decline in blood utilisation and therefore re-engineer, downsize 
operations, or merge with other regional blood services.[56,60]
In contrast, in many emerging and frontier economies, the focus 
of health authorities is still on modernising blood services to match 
quality levels comparable to those in the advanced economies and on 
establishing additional blood centres.[61-70] This expansion results in 
significant new investments and adds to the already large expenses 
of maintaining these services. In view of the poor cost-effectiveness 
of blood safety interventions and of transfusion therapy,[71-73] it 
is inappropriate use of limited financial resources. The decision 
to allocate more resources to supporting the product-focused 
transfusion model rather than the patient-centric PBM model could 
be likened to the establishment of landlines in a geographical area 
bare of communication infrastructure rather than setting up highly 
effective and much less costly mobile phone networks de novo.
In view of the burgeoning clinical data on adverse transfusion 
outcomes, the ongoing blood safety issues, the pervasive blood 
sourcing problems and the overall health-economic constraints, 
it would be both unethical and paradoxical to continue to invest 
Table 1. Summary of study results from the Western Australia Patient Blood Management Program, 2008 - 2012 (N=605 046), 
comparing baseline year (2008/09) with year 6 (2013/14) (adapted from Leahy et al.[40])
Patient outcomes Adjusted ratios (95% CI) p-value
In-hospital mortality 0.72 (0.67 - 0.77) <0.001
Hospital-acquired infections 0.79 (0.73 - 0.86) <0.001
Acute myocardial infarction/stroke 0.69 (0.58 - 0.82) <0.001
Length of hospital stay 0.85 (0.84 - 0.87) <0.001
All-cause emergency readmission 1.06 (1.02 - 1.10) <0.001
Key programme indicators Change
Preoperative anaemia 21% to 14% 0.001
Pre-transfusion haemoglobin 7.9 g/dL to 7.3 g/dL <0.001
Single-unit transfusions 33% to 64% <0.001
Type of blood product Reduction of units transfused
Red blood cells 41% <0.001
Plasma 47% <0.001
Platelets 27% <0.001
Economic indicators
Blood product cost reduction AUD18.5 million
Activity-based cost reduction (estimate) AUD80 - 100 million
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financial and human resources into the fading model of traditional 
blood banking while neglecting the implementation of PBM.[74]
Seizing the opportunity to improve 
SA’s health status and patient safety 
while saving costs
With combined support from both the public and private sectors, 
including the professional medical societies, academia, healthcare 
providers, funders, blood services and patient organisations and 
the endorsement of SA’s National Department of Health, a guiding 
coalition of PBM champions should take the opportunity to establish 
PBM as a new standard of care that offers a win-win scenario.[75]
PBM has become a national priority of the Australian Commission 
on Safety and Quality in Health Care,[76] and stakeholders in the 
public and private healthcare sectors of other countries have 
the opportunity to learn from the results of the state-wide PBM 
quality, safety and effectiveness initiative in Western Australia that 
significantly improved outcomes and achieved a sizeable cost and 
resource utilisation reduction.[40] They may benefit from the freely 
available multidisciplinary clinical PBM guidelines and algorithms.
[77-83] With local adaptations they may also use the European 
Commission’s guides for hospitals and health authorities on how 
to implement PBM sustainably as a national standard of care.[84,85] 
Additional lessons can be learned from blood services in foreign 
countries that are now embracing implementation of PBM as one of 
their core activities.[86-88]
Compelling evidence, newly gained international experience and 
many freely available tools and templates are now allowing progress 
to be quickly achieved with a series of single, evidence-based PBM 
interventions, or preferably PBM pilot programmes to be started in 
both the public and private sectors, gradually adjusting and refining 
contents to local needs and finally implementing PBM as a national 
standard of care.
Discussion
This article first describes why in many clinical settings the 
transfusion paradigm is fading while the PBM paradigm is rising. 
Overall, the evidence demonstrates that correcting anaemia 
through stimulated erythropoiesis, minimising blood loss through 
anaesthetic and surgical techniques, and optimising coagulation 
status before and during surgical or other interventions are 
associated with significantly better outcomes and less cost than the 
decades-old practice of transfusing allogeneic blood components. 
Then, the authors explain why implementation of PBM represents 
a solution to many of SA’s health, healthcare and economic 
challenges. PBM would effectively reduce the prevalence of anaemia, 
which owing to the country’s specific circumstances is higher 
than in many other countries. In combination with optimised 
bleeding and coagulation management, this reduction would have 
a positive effect on child and maternal mortality. Overall, based 
on international study results and in the context of secondary 
analysis of the SASOS, a large number of hospitalised medical and 
surgical patients would benefit from PBM. Its implementation 
would also decrease the demand for allogeneic blood components, 
thus easing the chronic pressure on the nation’s blood supply, 
which has a high number of donor restrictions as a result of 
HIV-related and other transmissible diseases. PBM would also 
contribute to socioeconomic improvements. Fewer complications, 
reduced morbidity and reduced hospital length of stay could lead 
to significant cost savings that could be reallocated to other areas 
of unmet clinical need. Optimal anaemia management, central to 
PBM, would also improve the cognitive development of children 
and adolescents, thus positively influencing productivity and the 
gross domestic product and the quality of life in SA.
The authors also allude to an important cultural aspect when 
it comes to the implementation of PBM: health authorities have 
traditionally focused on the supply of, not the demand for, blood. 
For decades, the legislation and administration of the ‘blood sector’ 
revolved around the concept that red blood cell transfusion is 
the only way of treating anaemia and blood loss. Therefore, the 
permanent and ubiquitous availability of safe donor blood was 
considered indispensable to keep clinical services operational, while 
the financial aspects of blood safety measures played only a minor 
role. However, with the introduction of evidence-based patient and 
disease management through PBM, other treatment options are now 
preferred, and in many clinical scenarios, blood transfusions are less 
frequently used or have even become obsolete.
Although this reversal of trends can now be observed in many 
modern healthcare systems, it may be challenging for health 
authorities to change focus, particularly when current efforts are still 
geared towards expansion of blood services. PBM will clearly impact 
a lot more on reducing the number of transfused blood components 
than any effort of the blood centres to increase the number of blood 
collections.
This article should be understood as a call to action to significantly 
improve the quality, safety and effectiveness of healthcare in SA. 
First, health authorities, medical professionals, funders and all other 
relevant stakeholders need to be thoroughly informed about the 
evidence on the multiple wins with PBM. This knowledge should 
lead to their acknowledgement and official endorsement of PBM 
and active support to implement it. Second, multidisciplinary peer-
reviewed guidelines, algorithms and other useful tools for PBM, that 
have already been developed in other parts of the world and are freely 
accessible, need to be adapted to the local needs of SA. This should 
primarily take place with the active involvement of all the relevant 
professional medical societies in SA. Third, PBM pilot projects in 
the public and private sectors should be carried out to test and refine 
PBM in the current healthcare framework, and finally, PBM should 
be implemented as a mandatory national standard of care.
Conclusions
The rapid implementation of PBM as a new standard of care is an 
urgent need. It offers the opportunity to sustainably and significantly 
improve the health status of the people of SA, with the potential of 
enormous savings for the healthcare system. 
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